These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 32259852)
1. Textural features in FDG-PET/CT can predict outcome in melanoma patients to treatment with Vemurafenib and Ipililumab. Dittrich D; Pyka T; Scheidhauer K; Lütje S; Essler M; Bundschuh RA Nuklearmedizin; 2020 Jun; 59(3):228-234. PubMed ID: 32259852 [TBL] [Abstract][Full Text] [Related]
2. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Sachpekidis C; Kopp-Schneider A; Hakim-Meibodi L; Dimitrakopoulou-Strauss A; Hassel JC Melanoma Res; 2019 Apr; 29(2):178-186. PubMed ID: 30653029 [TBL] [Abstract][Full Text] [Related]
3. Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661 [TBL] [Abstract][Full Text] [Related]
4. Absolute number of new lesions on Anwar H; Sachpekidis C; Winkler J; Kopp-Schneider A; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):376-383. PubMed ID: 29124281 [TBL] [Abstract][Full Text] [Related]
5. Longitudinal studies of the Sachpekidis C; Anwar H; Winkler JK; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A Cancer Immunol Immunother; 2018 Aug; 67(8):1261-1270. PubMed ID: 29872898 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of baseline metabolic tumor volume measured on Ito K; Schöder H; Teng R; Humm JL; Ni A; Wolchok JD; Weber WA Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):930-939. PubMed ID: 30488098 [TBL] [Abstract][Full Text] [Related]
7. Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors. Annovazzi A; Vari S; Giannarelli D; Pasqualoni R; Sciuto R; Carpano S; Cognetti F; Ferraresi V Clin Nucl Med; 2020 Mar; 45(3):187-194. PubMed ID: 31977479 [TBL] [Abstract][Full Text] [Related]
8. The role of interim Sachpekidis C; Anwar H; Winkler J; Kopp-Schneider A; Larribere L; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1289-1296. PubMed ID: 29478079 [TBL] [Abstract][Full Text] [Related]
9. Textural Parameters of Tumor Heterogeneity in ¹⁸F-FDG PET/CT for Therapy Response Assessment and Prognosis in Patients with Locally Advanced Rectal Cancer. Bundschuh RA; Dinges J; Neumann L; Seyfried M; Zsótér N; Papp L; Rosenberg R; Becker K; Astner ST; Henninger M; Herrmann K; Ziegler SI; Schwaiger M; Essler M J Nucl Med; 2014 Jun; 55(6):891-7. PubMed ID: 24752672 [TBL] [Abstract][Full Text] [Related]
10. [Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma]. Tietze JK; Heppt M; Angelova D; Ruzicka T; Berger F; Berking C Hautarzt; 2017 Aug; 68(8):632-638. PubMed ID: 28382381 [TBL] [Abstract][Full Text] [Related]
11. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Sachpekidis C; Larribere L; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A; Hassel JC Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):386-96. PubMed ID: 25359635 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma. Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144 [TBL] [Abstract][Full Text] [Related]
13. FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab. Iravani A; Wallace R; Lo SN; Galligan A; Weppler AM; Hicks RJ; Sandhu S Radiology; 2023 May; 307(3):e221180. PubMed ID: 36853183 [TBL] [Abstract][Full Text] [Related]
15. Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma. Cheng NM; Fang YH; Chang JT; Huang CG; Tsan DL; Ng SH; Wang HM; Lin CY; Liao CT; Yen TC J Nucl Med; 2013 Oct; 54(10):1703-9. PubMed ID: 24042030 [TBL] [Abstract][Full Text] [Related]
16. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739 [TBL] [Abstract][Full Text] [Related]
17. Textural features and SUV-based variables assessed by dual time point 18F-FDG PET/CT in locally advanced breast cancer. Garcia-Vicente AM; Molina D; Pérez-Beteta J; Amo-Salas M; Martínez-González A; Bueno G; Tello-Galán MJ; Soriano-Castrejón Á Ann Nucl Med; 2017 Dec; 31(10):726-735. PubMed ID: 28887761 [TBL] [Abstract][Full Text] [Related]
18. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. Iravani A; Osman MM; Weppler AM; Wallace R; Galligan A; Lasocki A; Hunter MO; Akhurst T; Hofman MS; Lau PKH; Kee D; Au-Yeung G; Sandhu S; Hicks RJ Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2776-2786. PubMed ID: 32338306 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of positron-emission tomography textural indices for malignancy of 18F-fluorodeoxyglucose-avid adrenal lesions. Thuillier P; Bourhis D; Schick U; Alavi Z; Guezennec C; Robin P; Kerlan V; Salaun PY; Abgral R Q J Nucl Med Mol Imaging; 2021 Mar; 65(1):79-87. PubMed ID: 30916534 [TBL] [Abstract][Full Text] [Related]
20. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT. Wachsmann JW; Ganti R; Peng F Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]